Presented by Bayer
Like other macrocyclic agents, Gadovist® is indicated for use in CNS. Gadovist® has also been approved in Canada for use in breast and kidney exams, as well as MRA and perfusion studies. It offers the most on-label indications of any MR macrocyclic agent available in Canada.1,2,3
The investment we’ve made in securing new indications for Gadovist® reflects the commitment Bayer makes to you and your patients. Like you, we believe “everyone deserves clear answers about their health”. Explore how to provide patients with an accurate diagnosis the first time. http://go.pardot.com/l/465562/2022-04-26/3jrhqx3
References
- Gadovist® Product Monograph. September 2021
- ProHance® Product Monograph. March 9, 2018
- Dotarem® Product Monograph. April 23, 2018